Age-related difference in susceptibility of ApcMin/+ mice towards the chemopreventive efficacy of dietary aspirin and curcumin

British Journal of Cancer

Volumn 88, Issue 9, 2003, Pages 1480-1483

  Perkins, S ^a   Clarke, A R ^b   Steward, W ^a   Gescher, A ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

ApcMin + mice; Aspirin; Chemoprevention; Curcumin

Indexed keywords

ACETYLSALICYLIC ACID; CURCUMIN;

ADENOMA; AGE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; INTESTINE POLYP; LIFESPAN; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGENY; WEANING;

ADENOMA; ADMINISTRATION, ORAL; AGING; ANIMALS; ANTICARCINOGENIC AGENTS; ASPIRIN; CURCUMIN; FEMALE; GENES, APC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTESTINAL NEOPLASMS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC;

EID: 0038751698     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600900     Document Type: Article

References (25)

1. Barnes CJ, Lee M (1998) Chemoprevention of spontaneous intestinal adenomas in the adenomatous polyposis coli Min mouse model with aspirin. Gastroenterology 114: 873-877
2. Boolbol SK, Dannenberg AJ, Chadburn A, Martucci C, Guo XJ, Ramonetti JT, Abreu-Goris M, Newmark HL, Lipkin ML, DeCosse JJ, Bertagnolli MM (1996) Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res 56: 2556-2560
3. Chiu CH, McEntee MF, Whelan J (2000) Discordant effect of aspirin and indomethacin on intestinal tumor burden in Apc(Min/+)mice. Prostaglandins Leukot Essent Fatty Acids 62: 269-275
4. Findlay JW, DeAngelis RL, Kearney MF, Welch RN, Findlay JM (1981) Analgesic drugs in breast milk and plasma. Clin Pharmacol Ther 29: 625-633
5. Ireson CR, Orr S, Jones DJL, Verschoyle, RD, Lim CK, Williams ML, Howells L, Plummer S, Jukes R, Steward WP, Gescher AJ (2001) Identification of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and rat plasma and evaluation of their ability to interfere with phorbol ester-induced prostaglandin E-2 production. Cancer Res 61: 1058-1064
6. Jacoby RF, Cole CE, Tutsch K, Newton MA, Kelloff G, Hawk ET, Lubet RA (2000a) Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos. Cancer Res 60: 1864-1870
7. Jacoby RF, Seibert K, Cole CE, Kelloff G, Lubet RA (2000b) The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the Min mouse model of adenomatous polyposis. Cancer Res 60: 5040-5044
8. Kinzler KW, Vogelstein B (1996) Lessons from hereditary colorectal cancer. Cell 87: 159-170
9. Luongo C, Moser AR, Gledhill S, Dove WF (1994) Loss of Apc+ in intestinal adenomas from Min mice. Cancer Res 54: 5947-5952
10. Mahmoud NN, Carothers AM, Grunberger D, Bilinski RT, Churchill MR, Martucci C, Newmark HL, Bertagnolli MM (2000) Plant phenolics decrease intestinal tumors in an animal model of familial adenomatous polyposis. Carcinogenesis 21: 921-927
11. Mahmoud NN, Dannenberg AJ, Mestre J, Bilinski RT, Churchill MR, Martucci C, Newmark H, Bertagnolli MM (1998) Aspirin prevents tumors in a murine model of familial adenomatous polyposis. Surgery 124: 225-231
12. Moser AR, Pitot HC, Dove WF (1990) A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science 247: 322-324
13. Needs CJK, Brooks PM (1985) Clinical pharmacokinetics of the salicylates. Clin Pharmacokinet 10: 164-177
14. Orner G, Dashwood W, Blum C, Diaz G, Li Q, Al-Fageeh M, Tebbutt N, Heath J, Ernst M, Dashwood R (2002) Response of Apc (min) and A33 (deltaNbeta-cat) mutant mice to treatment with tea, sulindac, and 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP). Mutat Res 506-507(C): 121
15. Perkins S, Verschoyle RD, Hill K, Parveen I, Threadgill MD, Sharma RA, Williams ML, Steward WP, Gescher AJ (2002) Chemopreventive efficacy and pharmacokinetics of curcumin in the Min/+ mouse, a model of familial adenomatous polyposis. Cancer Epidemiol Biomarkers Prey 11: 535-540
16. Plummer SM, Holloway KA, Manson MM, Munks RJ, Kaptein A, Farrow S, Howells L (1999) Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-kappaB activation via the NIK/IKK signalling complex. Oncogene 18: 6013-6020
17. Min/+ murine model of colon carcinogenesis. BMC Cancer 2: 19
18. Min/+ mouse by piroxicam: kinetics, strain effects and resistance to chemosuppression. Carcinogenesis 20: 51-58
19. Sansom OJ, Stark LA, Dunlop MG, Clarke AR (2001) Suppression of intestinal and mammary neoplasia by lifetime administration of aspirin in Apc(Min/+) and Apc(Min/+), Msh2(-/-) mice. Cancer Res 61: 7060-7064
20. Schoenfeld A, Bar Y, Merlon P, Ovadia Y (1992) NSAIDs: maternal and fetal considerations. Am J Reprod Immunol 28: 141-147
21. Shoemaker AR, Moser AR, Dove WF (1995) N-Ethyl-N-nitrosourea treatment of multiple intestinal neoplasia (Min) mice: age-related effects on the formation of intestinal adenomas, cystic crypts, and epidermoid cysts. Cancer Res 55: 4479-4485
22. Strumia MM, Sample AB, Hart ED (1954) An improved micro hematocrit method. Am J Clin Pathol 24: 1016-1024
23. Torrance CJ, Jackson PE, Montgomery E, Kinzler KW, Vogelstein B, Wissner A, Nunes M, Frost P, Discafani CM (2000) Combinatorial chemoprevention of intestinal neoplasia. Nat Med 6: 1024-1028
24. Vane JR (1971) Inhibition of prostaglandin synthesis as a mechanism of action of aspirin-like drugs. Nat New Biol 231: 232-235
25. Williamson SL, Kartheuser A, Coaker J, Kooshkghazi MD, Fodde R, Burn J, Mathers JC (1999) Intestinal tumorigenesis in the Apc1638N mouse treated with aspirin and resistant starch for up to 5 months. Carcinogenesis 20: 805-810